Skip to NavigationSkip to content

Novartis cuts more than 2500 jobs in Switzerland and the UK

Published on 25/09/18 at 10:41am

Swiss multinational Novartis are set to cut thousands of jobs across Europe in an effort to boost profitability. The move comes as part of a major restructuring which will take place over the next four years.

The multibillion pound drugmaker announced today that they are culling 2,200 employees from their 13,000 person strong Swiss workforce, while news got out that a further 400 workers are set to lose their jobs in Grimsby in the North of England.

In total 1,500 jobs will be cut from production sites in Switzerland, in Basel, Stein, Locarno and Schweizerhalle, while a further 700 business services positions are set to be transferred elsewhere. Meanwhile 400 workers are set to lose their jobs in the United Kingdom, as Novartis’ Grimsby production plant is scheduled for closure by 2020.

The Grimsby plant, which has been in production for more than half a century, is one of the town’s most stable employers.  

In a statement the company said “Novartis has been a part of the Grimsby community for many years so this has been a very difficult decision. The Grimsby site is an effective, well-running operation that is testament to the hard-working and dedicated employees.”

Novartis also made clear that the closure was not related to Brexit but was instead part of major restructuring as part of an effort to increase profitability around the world.

Louis Goss

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches